clobazam has been researched along with Adverse Drug Event in 6 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several studies suggest antiseizure effects also beyond these three epilepsy syndromes." | 5.91 | Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 5.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| "To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days)." | 5.40 | Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. ( Bekersky, I; Harris, SI; Isojarvi, J; Lee, D; Tolbert, D, 2014) |
| "Epidiolex® (CBD) is FDA-approved for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC)." | 3.30 | Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. ( Felton, E; Georgieva, D; Gidal, BE; Hartkopf, K; Hawk, L; Hsu, D; Langley, J; Margolis, A; Struck, A, 2023) |
| "Several studies suggest antiseizure effects also beyond these three epilepsy syndromes." | 1.91 | Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 1.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| "To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days)." | 1.40 | Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. ( Bekersky, I; Harris, SI; Isojarvi, J; Lee, D; Tolbert, D, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Kühne, F | 1 |
| Becker, LL | 1 |
| Bast, T | 1 |
| Bertsche, A | 1 |
| Borggraefe, I | 1 |
| Boßelmann, CM | 1 |
| Fahrbach, J | 1 |
| Hertzberg, C | 1 |
| Herz, NA | 1 |
| Hirsch, M | 1 |
| Holtkamp, M | 1 |
| Janello, C | 1 |
| Kluger, GJ | 1 |
| Kurlemann, G | 1 |
| Lerche, H | 1 |
| Makridis, KL | 1 |
| von Podewils, F | 1 |
| Pringsheim, M | 1 |
| Schubert-Bast, S | 1 |
| Schulz, J | 1 |
| Schulze-Bonhage, A | 1 |
| Steinbart, D | 1 |
| Steinhoff, BJ | 1 |
| Strzelczyk, A | 1 |
| Syrbe, S | 1 |
| De Vries, H | 1 |
| Wagner, C | 1 |
| Wagner, J | 1 |
| Wilken, B | 1 |
| Prager, C | 1 |
| Klotz, KA | 1 |
| Kaindl, AM | 1 |
| Georgieva, D | 1 |
| Langley, J | 1 |
| Hartkopf, K | 1 |
| Hawk, L | 1 |
| Margolis, A | 1 |
| Struck, A | 1 |
| Felton, E | 1 |
| Hsu, D | 1 |
| Gidal, BE | 1 |
| Porcari, GS | 1 |
| Fu, C | 1 |
| Doll, ED | 1 |
| Carter, EG | 1 |
| Carson, RP | 1 |
| Tolbert, D | 1 |
| Harris, SI | 1 |
| Bekersky, I | 1 |
| Lee, D | 2 |
| Isojarvi, J | 2 |
| Peng, G | 1 |
| Sperling, MR | 1 |
2 trials available for clobazam and Adverse Drug Event
| Article | Year |
|---|---|
Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Drug Resistant E | 2023 |
Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Dose-Respons | 2016 |
4 other studies available for clobazam and Adverse Drug Event
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug-Related Side Effects an | 2023 |
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Topics: Adolescent; Anticonvulsants; Attention; Cannabidiol; Cannabis; Child; Child, Preschool; Clobazam; Dr | 2018 |
Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.
Topics: Adult; Aged; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Clobazam; Drug-Related Side Effect | 2014 |